medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 3

<< Back Next >>

Ann Hepatol 2012; 11 (3)

Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study

Ponziani FR , Milani A, Gasbarrini A, Zaccaria R, Viganò R, Donato MF, Morelli MC, Miglioresi L, Pasulo L, Rendina M, Di Paolo D, Marino M, Toniutto P, Fagiuoli S, Pompili M

Language: English
References: 35
Page: 338-342
PDF size: 75.28 Kb.


ABSTRACT

Introduction. Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome. Results. Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3 (35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p ‹ 0.05). Conclusion. In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don’t show an EVR are not likely to achieve a SVR.


REFERENCES

  1. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31: 54-560.

  2. Simmonds P, Buck J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.

  3. Kamal SM, Imad AN. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 2008; 47: 1371-83.

  4. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. Hepatology 2011; 54: 1250-62.

  5. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-32.

  6. Antaki N, Craxi A, Kamal SM, Moucari R, Van der Merwe S, Haffar S, Gadano A, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2009; 10: 335-42.

  7. El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996; 3: 261-4.

  8. El-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital. J Gastroenterol Hepatol 1999; 31: 472-5.

  9. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172–4.

  10. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002; 35: 82-5.

  11. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, Al-Ahdal MN, Mayet I, Khan MQ, Kessie G. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568–74.

  12. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-7.

  13. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-66.

  14. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, et al. Pegylated interferon alpha- 2b plus ribavirine in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.

  15. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, et al; Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-67.

  16. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J of Med Vir 2009; 81: 1576–83.

  17. Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, Vezali E, Mihas C, Mariolis-Sapsakos T, Koutsounas S, Paraskevas E, Saroglou G. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. J Viral Hepat 2009; 16: 738-42.

  18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.

  19. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., HaussingerD, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  20. Ferenci P, Laferl H, Sherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, et al; Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.

  21. Elefsiniotis IS, Vezali E, Mihas C, Saroglou G. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 2009; 52: 247-51.

  22. Adam R, McMaster P, O’Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2009; 12: 1231-43.

  23. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-56.

  24. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, Nigel Girgrah N, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-21.

  25. Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, et al. Clinical trial: peg-interferon alfa- 2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450-7.

  26. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-9.

  27. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.

  28. Berenguer M, Aguilera V, Prieto M, Rayón JM, Juan FS, Prieto M. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-46.

  29. Dinges S, Morard I, Heim M, Dufour JF, Müllhaupt B, Giostra E, Clavien PA, Mentha G, Negro F; Swiss Association for the Study of the Liver (SASL 17). Pegylated interferonalpha2a/ ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009; 11: 33-9.

  30. Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, Lozano- Rey JM, De la Cruz-Lombardo J, Rodrigo-López JM. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc 2010; 42: 666-8.

  31. Mudawi H, Helmy A, Kamel Y, Al Saghier M, Al Sofayan M, Al Sebayel M, Khalaf H, et al. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: Natural history and predictors of outcome. Ann Saudi Med 2009; 29: 91-7.

  32. Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, et al. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci 2011; 56: 1848-52.

  33. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  34. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.

  35. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer 2009; 124: 690-7.




2020     |     www.medigraphic.com